signal/raiseTrack rounds
Series BHealthtech & bio · Tokyo

Boston Medical Sciences raises ¥5.55bn Series B for laxative-free AI colon cancer screening

Japan Growth Capital Investment Corporation, Global Brain and Beyond Next Ventures co-led the round, which the Tokyo company will use to prepare a Japanese launch and push into the US.

s/rFunding deskEast Asia · 3 min read

Boston Medical Sciences, a Tokyo start-up developing an AI-based screening test for colorectal cancer, raised ¥5.55bn (about $35.1m) in a Series B round, the company announced on 13 November 2026.

The round was an equity issue of new shares co-led by Japan Growth Capital Investment Corporation, whose assets are managed by Nomura Sparks Investment, together with Global Brain and Beyond Next Ventures. The company did not name other participants and did not disclose a valuation.

The Nikkei reported the raise on the same day and said the company was aiming to bring its laxative-free test into practical use in early 2027.

“We take the weight of ¥5.55bn in funding as a responsibility to move our development and business forward.”Masaki Okamoto, Founder and CEO, Boston Medical Sciences (translated)

What Boston Medical Sciences does

The company is building what it calls a laxative-free virtual endoscopy system. Instead of asking patients to drink laxatives and undergo a camera examination, the system takes CT images of the abdomen and uses AI to remove stool from the pictures digitally, then builds a three-dimensional view of the bowel in which polyps can be spotted.

Bowel preparation with laxatives is one of the reasons people avoid colon cancer checks. In its statement, Nomura Sparks Investment noted that Japan's screening rates for colorectal cancer tend to be lower than those of other countries.

The product is not yet approved. Japan's health ministry has designated it for priority review as a software medical device, and the company said it had completed a domestic clinical trial. In the US, it received Breakthrough Device Designation from the Food and Drug Administration in May 2026 and was accepted into the agency's TAP pilot programme in June. The company stressed that neither designation amounts to marketing approval.

Who invested and what the money is for

Global Brain and Beyond Next Ventures were already shareholders. Beyond Next Ventures backed the company before its Series A, and Global Brain joined in that round. Katsuya Hashizume, a partner at Beyond Next Ventures, said the company had finished its domestic trial three and a half years after it was founded and was now close to commercial use in Japan.

Boston Medical Sciences said it would split the money across three areas. The first is research and clinical development, covering AI and image analysis, clinical evidence and regulatory work in Japan and the US. The second is preparing to sell in Japan, including work with hospitals, quality assurance and hiring. The third is overseas expansion, mainly in the US, where it plans partnerships and a business plan adapted to the local health system.

Founder and chief executive Masaki Okamoto is a physician who previously worked as a researcher and faculty member at Harvard Medical School and Massachusetts General Hospital. In the announcement he said he saw the size of the raise as a responsibility to move both development and the business forward.

The funding so far

The company was incorporated in April 2023. Later that year it announced a round of about ¥400m, according to the Nikkei. In February 2025 it raised ¥930m in a Series A, with new investors including JIC Venture Growth Investments, Global Brain, East Japan Railway, Mitsubishi UFJ Capital and others, and Beyond Next Ventures following on, according to BRIDGE.

The Series B is several times larger than those earlier rounds put together. The company did not give a cumulative total.

The Nikkei's weekly round-up of Japanese start-up fundraising for 9 to 13 November listed Boston Medical Sciences alongside larger and smaller raises by companies including mobility firm newmo, which raised ¥20.8bn, and shared-ride operator NearMe, which raised about ¥520m.

Company website: b-ms.tech